Associated Papers
Profiling of HER2, KRAS, and PIK3CA mutations in uterine cervical neuroendocrine carcinoma and implications for oncogenic driver targeting therapy.
Chao WR et al.
Cancer Genetics, 2025
EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features.
Alvarez K et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2017
Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY et al.
Lung Cancer (amsterdam, Netherlands), 2014
Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.
Cote ML et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 2012
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H et al.
The Journal of Clinical Investigation, 2011
c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes.
Monsel G et al.
Oncogene, 2010
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
Schönleben F et al.
Langenbeck's Archives of Surgery, 2008
PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.
Kato S et al.
International Journal of Cancer, 2007
Select a paper to view details